Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

Model scores of the 29,894 trials active now.

Model score 32% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (1,598 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-12-20. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: carcinomaadvancedtherapypatientsmetastatic
  Phrases that lowered it: the studytreatment ofglobalblindwithin weeks
• Sponsor's past termination rate: 14.8% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 399 (raises risk) · Sponsor's track record
• Sponsor's past trials: 853 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Blinding: double (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Disease area, dermatology: No (lowers risk) · Disease area
• Number of arms: 2 (raises risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma NCT01334112 · started 2011 · scored riskier than 76% of active trials completed
• Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. NCT01035229 · started 2010 · scored riskier than 59% of active trials completed
• Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma NCT01273662 · started 2011 · scored riskier than 48% of active trials completed
• A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer NCT01911273 · started 2013 · scored riskier than 98% of active trials terminated
• A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100) NCT03289533 · started 2017 · scored riskier than 62% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.